Passage BIO, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| (in thousands, except share and per share data) · · 2025 · · 2024 | ||||||
| Operating expenses: · · · · · | ||||||
| Research and development | | $23,276 | | $40,179 | ||
| General and administrative | | 19,875 | | 24,988 | ||
| Impairment of long-lived assets | | | 6,145 | | | 5,233 |
| Loss from operations | | (49,296) | | (70,400) | ||
| Other income (expense), net | | 3,774 | | 5,633 | ||
| Net loss | | $(45,522) | | $(64,767) | ||
| Per share information: | | | | | ||
| Net loss per share of common stock, basic and diluted | | $(14.35) | | $(21.04) | ||
| Weighted average common shares outstanding, basic and diluted | | 3,172,870 | | 3,078,665 | ||
| Comprehensive loss: | | | | | | |
| Net loss | | $(45,522) | | $(64,767) | ||
| Unrealized gain (loss) on marketable securities | | | (8) | | | 51 |
| Comprehensive loss | | $(45,530) | | $(64,716) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.